Zoetis Inc. $ZTS Shares Sold by Unisphere Establishment

Posted by Francis Steltz on Jul 25th, 2026

Unisphere Establishment reduced its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 41.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 2,800,000 shares of the company’s stock after selling 2,000,000 shares during the period. Zoetis accounts for approximately 2.8% of Unisphere Establishment’s investment portfolio, making the stock its 11th largest position. Unisphere Establishment’s holdings in Zoetis were worth $330,988,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $28,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis during the fourth quarter worth about $30,000. Root Financial Partners LLC raised its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Finally, Elyxium Wealth LLC purchased a new position in Zoetis during the fourth quarter worth about $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Insider Activity at Zoetis

In other news, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. TD Cowen decreased their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Morgan Stanley decreased their price objective on Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a report on Wednesday. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $119.50.

Get Our Latest Analysis on Zoetis

Zoetis Trading Up 1.0%

NYSE ZTS opened at $75.32 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $31.58 billion, a P/E ratio of 12.49, a PEG ratio of 1.16 and a beta of 0.75. The firm’s 50-day moving average is $77.29 and its two-hundred day moving average is $104.25. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.